These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30853418)

  • 1. Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite.
    Bruning JM; Wang Y; Oltrabella F; Tian B; Kholodar SA; Liu H; Bhattacharya P; Guo S; Holton JM; Fletterick RJ; Jacobson MP; England PM
    Cell Chem Biol; 2019 May; 26(5):674-685.e6. PubMed ID: 30853418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analogs of the Dopamine Metabolite 5,6-Dihydroxyindole Bind Directly to and Activate the Nuclear Receptor Nurr1.
    Kholodar SA; Lang G; Cortopassi WA; Iizuka Y; Brah HS; Jacobson MP; England PM
    ACS Chem Biol; 2021 Jul; 16(7):1159-1163. PubMed ID: 34165961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PGE1 and PGA1 bind to Nurr1 and activate its transcriptional function.
    Rajan S; Jang Y; Kim CH; Kim W; Toh HT; Jeon J; Song B; Serra A; Lescar J; Yoo JY; Beldar S; Ye H; Kang C; Liu XW; Feitosa M; Kim Y; Hwang D; Goh G; Lim KL; Park HM; Lee CH; Oh SF; Petsko GA; Yoon HS; Kim KS
    Nat Chem Biol; 2020 Aug; 16(8):876-886. PubMed ID: 32451509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into ligand-binding pocket formation in Nurr1 by molecular dynamics simulations.
    Windshügel B
    J Biomol Struct Dyn; 2019 Oct; 37(17):4651-4657. PubMed ID: 30582418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Guided Design of Nurr1 Agonists Derived from the Natural Ligand Dihydroxyindole.
    Sai M; Vietor J; Kornmayer M; Egner M; López-García Ú; Höfner G; Pabel J; Marschner JA; Wein T; Merk D
    J Med Chem; 2023 Oct; 66(19):13556-13567. PubMed ID: 37751901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining a Canonical Ligand-Binding Pocket in the Orphan Nuclear Receptor Nurr1.
    de Vera IMS; Munoz-Tello P; Zheng J; Dharmarajan V; Marciano DP; Matta-Camacho E; Giri PK; Shang J; Hughes TS; Rance M; Griffin PR; Kojetin DJ
    Structure; 2019 Jan; 27(1):66-77.e5. PubMed ID: 30416039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent synthetic and endogenous ligands for the adopted orphan nuclear receptor Nurr1.
    Jang Y; Kim W; Leblanc P; Kim CH; Kim KS
    Exp Mol Med; 2021 Jan; 53(1):19-29. PubMed ID: 33479411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro.
    Hammond SL; Safe S; Tjalkens RB
    Neurosci Lett; 2015 Oct; 607():83-89. PubMed ID: 26383113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin A2 Interacts with Nurr1 and Ameliorates Behavioral Deficits in Parkinson's Disease Fly Model.
    Rajan S; Toh HT; Ye H; Wang Z; Basil AH; Parnaik T; Yoo JY; Lim KL; Yoon HS
    Neuromolecular Med; 2022 Dec; 24(4):469-478. PubMed ID: 35482177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lethal Factor Domain-Mediated Delivery of Nurr1 Transcription Factor Enhances Tyrosine Hydroxylase Activity and Protects from Neurotoxin-Induced Degeneration of Dopaminergic Cells.
    Paliga D; Raudzus F; Leppla SH; Heumann R; Neumann S
    Mol Neurobiol; 2019 May; 56(5):3393-3403. PubMed ID: 30121937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression.
    Volakakis N; Tiklova K; Decressac M; Papathanou M; Mattsson B; Gillberg L; Nobre A; Björklund A; Perlmann T
    J Neurosci; 2015 Oct; 35(42):14370-85. PubMed ID: 26490873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
    Munoz-Tello P; Lin H; Khan P; de Vera IMS; Kamenecka TM; Kojetin DJ
    J Med Chem; 2020 Dec; 63(24):15639-15654. PubMed ID: 33289551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nur(R1)turing a notion on the etiopathogenesis of Parkinson's disease.
    Federoff HJ
    Neurotox Res; 2009 Oct; 16(3):261-70. PubMed ID: 19526279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nurr1 Activator 1,1-Bis(3'-Indolyl)-1-(p-Chlorophenyl)Methane Blocks Inflammatory Gene Expression in BV-2 Microglial Cells by Inhibiting Nuclear Factor κB.
    De Miranda BR; Popichak KA; Hammond SL; Jorgensen BA; Phillips AT; Safe S; Tjalkens RB
    Mol Pharmacol; 2015 Jun; 87(6):1021-34. PubMed ID: 25858541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nurr1 deficiency shortens free running period, enhances photoentrainment to phase advance, and disrupts circadian cycling of the dopamine neuron phenotype.
    Partington HS; Nutter JM; Eells JB
    Behav Brain Res; 2021 Aug; 411():113347. PubMed ID: 33991560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperation of nuclear fibroblast growth factor receptor 1 and Nurr1 offers new interactive mechanism in postmitotic development of mesencephalic dopaminergic neurons.
    Baron O; Förthmann B; Lee YW; Terranova C; Ratzka A; Stachowiak EK; Grothe C; Claus P; Stachowiak MK
    J Biol Chem; 2012 Jun; 287(24):19827-40. PubMed ID: 22514272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nurr1-Based Therapies for Parkinson's Disease.
    Dong J; Li S; Mo JL; Cai HB; Le WD
    CNS Neurosci Ther; 2016 May; 22(5):351-9. PubMed ID: 27012974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons.
    Kadkhodaei B; Alvarsson A; Schintu N; Ramsköld D; Volakakis N; Joodmardi E; Yoshitake T; Kehr J; Decressac M; Björklund A; Sandberg R; Svenningsson P; Perlmann T
    Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2360-5. PubMed ID: 23341612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease.
    Kim CH; Han BS; Moon J; Kim DJ; Shin J; Rajan S; Nguyen QT; Sohn M; Kim WG; Han M; Jeong I; Kim KS; Lee EH; Tu Y; Naffin-Olivos JL; Park CH; Ringe D; Yoon HS; Petsko GA; Kim KS
    Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8756-61. PubMed ID: 26124091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease.
    Zhang Z; Li X; Xie WJ; Tuo H; Hintermann S; Jankovic J; Le W
    CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):768-73. PubMed ID: 22483304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.